Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
150 participants
OBSERVATIONAL
2022-03-16
2041-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04134325
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00482053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who received IP in a Caribou-sponsored, special access program or IIT and provided informed
consent for the LTFS
Caribou-sponsored investigational therapy
N/A this is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caribou-sponsored investigational therapy
N/A this is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
* Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Caribou Biosciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Honor Health Research Institute
Scottsdale, Arizona, United States
University of California Irvine
Irvine, California, United States
University of California San Diego
La Jolla, California, United States
University of Colorado
Denver, Colorado, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Miami
Miami, Florida, United States
AdventHealth Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida, United States
Blood & Marrow Transplant Group of Georgia
Atlanta, Georgia, United States
Augusta University/Georgia Cancer Center
Augusta, Georgia, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
University of Kentucky
Lexington, Kentucky, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Regional Cancer Care Associates - Hackensack
Hackensack, New Jersey, United States
Atlantic Health System Cancer Care
Morristown, New Jersey, United States
Weill Cornell Medicine
New York, New York, United States
Icahn School of Medicine at Mt. Sinai
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Levine Cancer Center
Charlotte, North Carolina, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute - TriStar Health
Nashville, Tennessee, United States
Baylor Research Institute
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LTFS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.